SequelSEC

Arcadia Biosciences, Inc. RKDA

Crude Petroleum & Natural Gas · CIK 0001469443 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$4.75M
Fiscal year ended 2026-06-30
Operating income
-$3.80M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$5.74MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$2.79Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.4×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Crude Petroleum & Natural Gas filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.0%0th
Current ratio3.09x89th
SBC / revenue4.8%83th
Operating margin-51.5%17th
Net margin-48.1%18th
Gross margin36.2%26th
Revenue YoY growth-3.7%40th

Arcadia Biosciences, Inc. (RKDA) reported revenue of $4.75M and net income of -$11.13M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Arcadia Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Crude Petroleum & Natural Gas.

Income

Arcadia Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$4.75M
Cost of revenue$3.10M
Gross profit$1.64M
Operating income-$3.80M
Net income-$11.13M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$5.44M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Arcadia Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$4.18M
Total assets$5.89M
Current assets$5.74M
Total liabilities$5.26M
Current liabilities$1.65M
Total equity incl. NCI$633.00K
Temporary (mezzanine) equityUnavailable
Inventory$930.00K
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

Arcadia Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$2.50M
Capital expendituresUnavailable
Investing cash flow$0
Financing cash flow$5.34M
Net change in cash$2.80M
Stock-based compensation$99.00K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Arcadia Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin34.6%
Operating margin-80.1%
FCF marginUnavailable
SBC / revenue2.1%
Current ratio3.49x
Revenue YoY growth-12.2%
Net margin-234.5%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RKDA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K/A · Filed 2026-04-30View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-14View SEC filing

Companies in the same industry

AESI AGIG ALTX AMPY ANNA APA AR BATL BDCO BKV BRN BSIN

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.